Spiriva’s “All-Clear” On CV Safety From FDA Could Raise Bar For COPD Candidates
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency responds to preliminary trial results by lifting the safety alert linking the inhaled anticholinergic to risk of stroke.